Non-Interventional Post-Authorisation Safety Study (PASS) survey to evaluate the effectiveness of the Isatuximab Educational Materials, to minimise the Risk of Interference for blood typing (minor antigen) (positive indirect Coombs’ test).

03/05/2022
23/04/2024
EU PAS number:
EUPAS46988
Study
Finalised
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

Sanofi Isatuximab PASS survey protocol_PRAC_V1.4_21Oct2021_clean_EUPAS46988 for publication.pdf

English (1.85 MB - PDF) View document
Study results
Study report
Other information